Regular ArticleMannose-Coated Liposomal Hamycin (cas 1403-71-0) in the Treatment of Experimental Leishmaniasis in Hamsters

Add time:09/05/2019    Source:sciencedirect.com

Liposomal Hamycin (cas 1403-71-0) was found to elicit enhanced microbicidal activity and reduced toxicity in experimental leishmaniasis in a hamster model under in vivo conditions. Mannose-coated liposomal hamycin was seen to produce increased therapeutic efficacy as judged from the lowering of spleen parasite load. At an equivalent dose of 0.5 mg/kg, every 3 days for a total of three doses in 7 days, the mannose-coated liposomal hamycin was found to be most effective compared to either of the liposomal hamycin or the free hamycin. Because of the reduced toxicity as judged from the blood pathology, tissue histology, and specific enzyme level related to normal liver function, mannose-coated liposomal hamycin resulted in 80 to 100% survival for a period of 15-18 days. Hamycin intercalated in sterol-rich liposomes showed reduced hemolytic activity but comparable therapeutic efficacy as was found with ordinary liposomes.

We also recommend Trading Suppliers and Manufacturers of Hamycin (cas 1403-71-0). Pls Click Website Link as below: cas 1403-71-0 suppliers

Prev:Hamycin (cas 1403-71-0): Separation of toxicity and antifungal activity in mice
Next:RETRACTED: Hamycin (cas 1403-71-0) treatment of candidiasis in normal and diabetic rats)